Seelos Therapeutics, Inc. is a clinical-stage bio-pharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and in rare diseases. The Company’s portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York. Seelos’ common stock is traded on The Nasdaq Capital Market under the symbol "SEEL".